Teva seeks leave in levofloxacin damages
assessment.
As previously reported, the Federal Court of
Appeal (FCA) dismissed Teva's appeal on the quantification of
damages from infringement of Janssen's patent for
levofloxacin (LEVAQUIN). The FCA
rejected Teva's arguments, finding that the Federal Court did
not err in constructing the hypothetical world, and that the
Federal Court's factual findings were open to it on the
evidence. On March 26, 2018, Teva applied to the Supreme Court of
Canada for leave to appeal (docket no. 38033).
Supreme Court denies leave regarding natural health
product licence.
On April 12, 2018, the Supreme Court of Canada dismissed The
Winning Combination's leave to appeal (docket no. 37697). The Federal Court of Appeal decision
had set aside the order of mandamus compelling the Minister of
Health to grant a licence to The Winning Combination for its
natural health product, RESOLVE (as previously reported).